Looking to publish in Immunopharmacology and Immunotoxicology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowImmunopharmacology and Immunotoxicology publishes manuscripts on drug discovery, pre-clinical and clinical development of agents targeting the immune system, and immunotoxicology of defined drug compounds. It focuses on anti-inflammatory treatments, cancer immunotherapy, vaccines, small molecules, biologics, and cell-based therapies, and covers immune-mediated diseases, cancer immunology, infections, transplantation, allergy, chronic kidney disease, neurodegenerative disorders, immunodeficiencies, neurology, inflammatory atherosclerosis, and related areas. The journal considers mechanism-of-action studies, in vitro and pre-clinical animal studies, and non-interventional and interventional clinical studies.
Looking to publish in Immunopharmacology and Immunotoxicology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Immunopharmacology and Immunotoxicology accepts the following article types. Click on an article type to view submission instructions.
Original Manuscripts
Mini-Reviews
Review
Clinical Trials
Research Article
Brief Communication
Clinical Cases
Clinical Note
Letter
Recent Publications
Nano-enabled strategies for enhancing cancer immunotherapy: challenges, progress and perspective
Hazem Mathkour,
Pharmacovigilance analysis of vonoprazan: a disproportionality analysis based on the FDA adverse event reporting system database
Boyi Liu, Wenchao Zhang, Ao Han, Danna Chen
A comparative analysis of MSCs and their exosomes in osteoarthritis therapy: complementary roles and clinical translation
Nada Khairi Younis, Hayder Naji Sameer, Hasanain Amer Naji, M. M. Rekha, Laxmidhar Maharana, Anima Nanda, Vipasha Sharma, Ashish Singh Chauhan, Rasim M. Salih, Mohaned Adil, Farzaneh Yazdi
Statement of Retraction: Amygdalin Induces Apoptosis in Human Cervical Cancer Cell Line HeLa Cells
-
Omarigliptin attenuates thioacetamide-induced hepatic fibrosis in rats by activating SIRT1/Nrf2 and inhibiting NF-κB/TGF-β1 pathways
Abdulaziz Alarifi, Marwa Qadri, Daniyah A. Almarghalani, Ali Alquraini, Faisal K. Alkholifi, Fadhel A. Alomar, Moudi M. Alasmari, Aya A. Shokry, Passant E. Moustafa, Hany M. Fayed, Marwa E. Shabana
Frequently asked questions
How long does it take to publish?
Optional Accelerated Publication offers a final decision in as little as 3 weeks from submission, with peer review in approximately 2 weeks, online publication usually 1-2 weeks after acceptance, first proofs within 5 working days, and proof corrections requested within 48 hours.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite PremiumIs a cover letter required?
Journals may require authors to sign a letter certifying that legal and ethical requirements for humane treatment of animals have been met.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite PremiumWhat are the publication costs?
Institutional online-only subscription is USD 6,695.00 and print & online subscription is USD 9,791.00.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite Premium